{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:15:55Z","timestamp":1778616955995,"version":"3.51.4"},"reference-count":24,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephron"],"published-print":{"date-parts":[[2024]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Introduction:&lt;\/i&gt;&lt;\/b&gt; This study aimed to investigate the efficacy and safety of sucroferric oxyhydroxide (SFOH) versus sevelamer carbonate in controlling serum phosphorus (sP) in adult Chinese dialysis patients with hyperphosphataemia (sP &amp;gt;1.78 mmol\/L). &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; Open-label, randomised (1:1), active-controlled, parallel group, multicentre, phase III study of SFOH and sevelamer at starting doses corresponding to 1,500 mg iron\/day and 2.4 g\/day, respectively, with 8-week dose titration and 4-week maintenance (NCT03644264). Primary endpoint was non-inferiority analysis of change in sP from baseline to week 12. Secondary endpoints included sP over time and safety. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; 415 patients were screened; 286 were enrolled and randomised (142 and 144 to SFOH and sevelamer, respectively). Mean (SD) baseline sP: 2.38 (0.57) and 2.38 (0.52) mmol\/L, respectively. Mean (SD) change in sP from baseline to week 12: \u2013 0.71 (0.60) versus \u22120.63 (0.52) mmol\/L, respectively; difference (sevelamer minus SFOH) in least squares means (95% CI): 0.08 mmol\/L (\u22120.02, 0.18) with the lower limit of 95% CI above the non-inferiority margin of \u22120.34 mmol\/L. The SFOH group achieved target sP (1.13\u20131.78 mmol\/L) earlier than the sevelamer group (56.5% vs. 32.8% at week 4) and with a lower pill burden (mean 3.7 vs. 9.1 tablets\/day over 4 weeks of maintenance, respectively). Safety and tolerability of SFOH was consistent with previous studies, and no new safety signals were observed. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; SFOH effectively reduced sP from baseline and was non-inferior to sevelamer after 12 weeks of treatment but had a lower pill burden in Chinese dialysis patients with hyperphosphataemia; SFOH benefit-risk profile is favourable in Chinese patients. <\/jats:p>","DOI":"10.1159\/000531869","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T21:01:39Z","timestamp":1690232499000},"page":"22-33","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study"],"prefix":"10.1159","volume":"148","author":[{"given":"Jun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Walpen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Marty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milica","family":"Enoiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01660309"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.164"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000500053"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5414\/cnp74004"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08230811"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.58"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv006"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-016-1299-z"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2017.02.007"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2017.10.003"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12891"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04805-y"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-021-01241-5"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/nu7064661"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000444840"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5414\/CNP86S104"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20790-8"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000533"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79531-4"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft232"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.01.1055"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-02188-8"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw242"}],"container-title":["Nephron"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/nef\/article-pdf\/148\/1\/22\/4158630\/000531869.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/nef\/article-pdf\/148\/1\/22\/4158630\/000531869.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:40:04Z","timestamp":1745422804000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000531869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,16]]},"published-print":{"date-parts":[[2024,1,17]]}},"URL":"https:\/\/doi.org\/10.1159\/000531869","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.23723337","asserted-by":"subject"}]},"ISSN":["1660-8151","2235-3186"],"issn-type":[{"value":"1660-8151","type":"print"},{"value":"2235-3186","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]}}}